Business Overview: Trulieve Cannabis Corp. (OTC: TRLV)

---

Executive Summary

Trulieve Cannabis Corp. is one of the largest vertically integrated multi-state cannabis operators (MSOs) in the United States, cultivating, processing, and retailing cannabis products across roughly nine states, with a particularly dominant position in the Florida medical-cannabis market. The company controls the full supply chain — cultivation, processing/manufacturing, and dispensary retail — and operates a portfolio of branded products sold through its own retail footprint of over 225 dispensaries supplied by roughly 15 cultivation and processing facilities.

Trulieve reported FY2024 revenue of approximately $1.2 billion, with a gross margin near 60% and adjusted EBITDA of roughly $420 million, reflecting the scale advantages of vertical integration even as the broader U.S. cannabis industry contends with federal illegality (and its associated tax and banking constraints under IRC Section 280E), state-by-state regulatory variation, and persistent price compression from oversupply in several mature markets.

---

1. Core Business Model & How They Work

[ Licensed Cultivation (indoor/greenhouse) ] ➡️ [ Processing & Manufacturing (flower, edibles, vapes, concentrates) ] ➡️ [ Branded Products ] ➡️ [ Trulieve-Owned Dispensaries (225+) ] ➡️ [ Medical & Adult-Use Consumers ]

Key Operational Drivers

1. Full vertical integration: Trulieve owns the cannabis supply chain end-to-end in its core states — cultivation, processing, and retail — capturing margin at every step rather than relying on third-party wholesale relationships.
2. Florida market leadership: Florida, a large medical-only market with strict limited-license structure, is Trulieve's single largest and most profitable state, giving the company an outsized share of one of the country's largest state cannabis markets.
3. Multi-state geographic diversification: Beyond Florida, Trulieve operates across other medical and adult-use states, spreading regulatory and demand risk, though with Florida contributing a disproportionate share of profitability.
4. Brand-tiered product portfolio: Trulieve markets multiple branded product lines spanning value to premium price points, allowing it to capture different consumer segments within the same retail footprint.

---

2. Business Segments

Trulieve operates as a single vertically integrated cannabis operating segment across its multi-state footprint.

┌───────────────────────────────┐
│    Trulieve Cannabis Corp.      │
└───────────────┬────────────────┘
                │
      ┌─────────┴──────────┐
      ▼                     ▼
┌──────────────────┐  ┌─────────────────────┐
│ Florida (flagship,│  │ Other States          │
│ medical-only,      │  │ (medical/adult-use     │
│ largest profit      │  │ mix; PA, AZ, OH, GA,   │
│ contributor)         │  │ WV, MD, etc.)          │
└──────────────────┘  └─────────────────────┘

---

3. Product Portfolio

---

4. Competitive Landscape

             U.S. MULTI-STATE CANNABIS OPERATOR (MSO) LANDSCAPE
┌──────────────────────────────────────────────────────────────┐
│ High   [TRULIEVE] (Florida-dominant, vertically integrated)    │
│   ▲                                                             │
│ S │        Curaleaf        Green Thumb Industries               │
│ C │                                                              │
│ A │   Cresco Labs      Verano Holdings      Ayr Wellness         │
│ L │                                                              │
│ E │                                                              │
│ Low└─────────────────────────────────────────────────────────► │
│    Single-state           GEOGRAPHIC FOOTPRINT BREADTH    Multi-state│
└──────────────────────────────────────────────────────────────┘

• National MSO peers: Curaleaf Holdings, Green Thumb Industries, Verano Holdings, Cresco Labs, and Ayr Wellness are the primary multi-state competitors, each pursuing similar vertically integrated, multi-brand strategies across overlapping state markets.
• State-level competitors: In Florida specifically, Trulieve competes against other licensed Florida MSOs (such as Curaleaf and Verano's Florida operations) for medical-patient market share.
• Illicit market: In many states, the unregulated/illicit cannabis market remains a significant competitive factor, particularly where legal retail pricing (burdened by taxes and 280E economics) cannot compete on price.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Florida scale and license position: A leading share of licensed dispensaries and cultivation capacity in one of the largest limited-license medical markets in the country generates outsized, durable profitability.
• Full vertical integration: Owning cultivation through retail captures margin other operators give up to third parties and provides tighter control over product quality and supply.
• Large retail footprint: Over 225 dispensaries provide broad consumer reach and valuable retail real estate in markets with licensing caps that limit new competitor entry.

Risks

• Federal illegality (Section 280E): Cannabis remains a Schedule I/II controlled substance federally; Section 280E of the U.S. tax code disallows standard business-expense deductions, resulting in effective tax rates far above those of ordinary corporations, and banking access remains constrained.
• Price compression in mature markets: States with rapid license growth or oversupply (e.g., certain adult-use markets) have experienced significant wholesale and retail price declines, pressuring margins.
• Regulatory concentration risk: A large share of profitability depends on continued favorable Florida regulatory and licensing conditions (including the state's medical framework and any future adult-use legalization outcome).
• Capital markets access: Federal illegality limits access to traditional banking, lending, and major stock exchange listings, constraining capital-raising options relative to conventional corporations.

---

6. Financial Overview

---

7. Summary Conclusion

Trulieve has built one of the cannabis industry's strongest state-level moats by dominating Florida's large, limited-license medical market while running a fully vertically integrated operation that captures margin at every stage from cultivation to retail. That concentration is also its central risk: profitability leans heavily on Florida's regulatory status quo, and the company — like all U.S. cannabis operators — remains hostage to federal prohibition's tax (280E) and banking constraints, as well as to price competition both from well-capitalized MSO peers in its other states and from the illicit market where legal pricing cannot compete.